Sodium oxybate (Xyrem, Xywav)
What studies of Sodium oxybate (Xyrem, Xywav) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Sodium oxybate (Xyrem, Xywav) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Sodium oxybate (Xyrem, Xywav) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Sleep1 study · 1 (few people) person took Sodium oxybate (Xyrem, Xywav) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · up to 2g, once nightly (few people)
Sleep improved.
The evidence is very uncertain about the effect of sodium oxybate (Xyrem, Xywav) on sleep in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
1171 Hypersomnia Secondary to Long Covid (2024)
- People in the study
- 1 in the study
- Dose
- up to 2g, once nightly
- Outcome
- sleep inertia
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person took Sodium oxybate (Xyrem, Xywav) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · up to 2g, once nightly (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of sodium oxybate (Xyrem, Xywav) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
1171 Hypersomnia Secondary to Long Covid (2024)
- People in the study
- 1 in the study
- Dose
- up to 2g, once nightly
- Outcome
- return to school full time and reached normal functioning
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- 1171 Hypersomnia Secondary to Long Covid2024 · case report · 1 in the study